Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

otherapy were deemed eligible for consolidation treatment six to ten weeks after the sixth cycle with one course of Zevalin. Primary endpoints were complete response and hematological toxic effects and secondary endpoints were overall survival and progression-free survival.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Regulatory and Reimbursement Landscape Poland " an essential ... in the healthcare market and provides insights into ... Most importantly, the report provides valuable insights into ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... ... , ... , , , ... ...
... , ... ... ... ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 2Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 3Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 4Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6
(Date:8/28/2014)... UWDress.com, an internationally famous designer and leader ... fashionable assortment of fall bridesmaid dresses for ... customers, the company is now providing big discounts for ... fall bridesmaid outfits are offered in many fashionable colours. ... priced less than $190. UWDress.com’s kind officials always take ...
(Date:8/28/2014)... 29, 2014 Top10BestSEOHosting.com has recently ... that FatCow, Hostgator and Bluehost are the best ... ) has been working in the hosting industry ... is connected to multiple GB connections to ensure ... disruptions to customers’ websites. The great thing is ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Millennium Treatment ... in America is extremely large, and Millennium Treatment Group is ... and treatment that they need. , According to the ... more than 21 million Americans could have benefited from treatment ... those people received help. This means that there is a ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... worsen symptoms of multiple sclerosis (MS), a new study from ... vitamin D, smoking and Epstein Barr virus infection. Our study ... affecting MS patients," said lead researcher Dr. Mauricio Farez, of ... Multiple sclerosis is a disease of the nervous system ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Governor ... Microcredit Summit at a press conference; this event ... with the Ministry of Economy through the National Microenterprise ... from September 2nd to the 5th at the Convention ... , “It is a great responsibility for Yucatan to ...
Breaking Medicine News(10 mins):Health News:Fashionable Fall Bridesmaid Dresses From UWDress.com 2Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: